Certara (CERT) Projected to Release Earnings on Tuesday

Certara (NASDAQ:CERT) is anticipated to issue its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Certara to announce earnings of $0.10 per share and revenue of $98.0870 million for the quarter. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. Parties can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:30 AM ET.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Monday, May 11th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.02). Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. The firm had revenue of $106.92 million during the quarter, compared to analysts’ expectations of $106.13 million. During the same quarter last year, the company posted $0.14 EPS. The firm’s revenue was up .8% compared to the same quarter last year. On average, analysts expect Certara to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Certara Stock Performance

Certara stock opened at $8.10 on Monday. Certara has a 52 week low of $4.45 and a 52 week high of $13.88. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.88 and a current ratio of 1.88. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of -81.00 and a beta of 1.46. The company has a 50 day moving average price of $6.30 and a 200 day moving average price of $6.58.

Analyst Ratings Changes

CERT has been the subject of a number of research analyst reports. Robert W. Baird reduced their target price on Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Tuesday, May 12th. Barclays lowered their price target on Certara from $8.00 to $6.50 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Stephens dropped their price target on Certara from $10.00 to $9.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Morgan Stanley reduced their price objective on Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. Finally, KeyCorp decreased their price objective on Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a research report on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Certara currently has an average rating of “Hold” and an average target price of $8.85.

Institutional Trading of Certara

Several hedge funds and other institutional investors have recently modified their holdings of the company. Jain Global LLC acquired a new position in Certara in the 4th quarter worth about $356,000. Barclays PLC lifted its holdings in shares of Certara by 28.9% during the 4th quarter. Barclays PLC now owns 38,816 shares of the company’s stock valued at $342,000 after buying an additional 8,712 shares during the last quarter. Brooklyn Investment Group bought a new stake in shares of Certara in the 4th quarter valued at approximately $232,000. EntryPoint Capital LLC bought a new stake in shares of Certara in the 4th quarter valued at approximately $226,000. Finally, nVerses Capital LLC acquired a new position in Certara in the fourth quarter worth approximately $184,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.